| Malignant Pleural Effusions: Evaluating the psYchosocial Impact of Indwelling Pleural Catheters on Patients (NCT05372055) | Guy's and St Thomas' NHS Foundation Trust | 2022-05-09 |
| Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma (NCT05278975) | RS Oncology LLC | 2022-03-31 |
| A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions (NCT04914598) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2021-07-28 |
| A Multicenter Survey Study Into Patient Experience With Mobile Apps (NCT05130697) | National University of Ireland, Galway, Ireland | 2021-07-01 |
| Randomized Controlled Trial of Talc Instillation In Addition To Daily Drainage Through a Tunneled Pleural Catheter to Improve Rates of Outpatient Pleurodesis in Patients With Malignant Pleural Effusion (NCT04792970) | Duke University | 2021-03-18 |
| Interventions for Malignant Pleural Effusions Impact on Fatigue (NCT04793607) | Northumbria Healthcare NHS Foundation Trust | 2020-09-01 |
| Safety and Efficacy Study of Virus Activated Killer Immune Cells (VAK) for Malignant Pleural and Peritoneal Effusion (NCT05565014) | Sheng Hu | 2020-07-24 |
| Value of Additional Upfront Systematic Lung Ultrasound in the Workup of Patients With Unilateral Pleural Effusion (NCT04235998) | Naestved Hospital | 2020-02-17 |
| Quantitative Diaphragmatic Ultrasound Evaluation in Pleural Effusions : A Feasability Study (NCT04264325) | University Hospital, Strasbourg, France | 2020-01-31 |
| A Phase I Study Evaluating SCB-313(Recombinant Human TRAIL-Trimer Fusion Protein) for the Treatment of Malignant Pleural Effusion (NCT04123886) | Sichuan Clover Biopharmaceuticals, Inc. | 2020-01-08 |
| Ultrasound-guided Biopsy of the Pleura as a Supplement to Extraction of Fluid in Patients With One-sided Fluid in the Pleura (NCT04236037) | Naestved Hospital | 2019-11-11 |
| Safety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural Effusion (NCT04131231) | Peking Union Medical College | 2019-10-15 |
| Comparison of the Effectiveness of Povidone-Iodine Alone to Povidone-Iodine-Tetracycline Combination (NCT04039126) | University College Hospital, Ibadan | 2019-06-20 |
| Talc Outpatient Pleurodesis With Indwelling Catheter (NCT03973957) | The Cooper Health System | 2019-05-27 |
| A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion (NCT03597009) | UNC Lineberger Comprehensive Cancer Center | 2019-03-06 |
| A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites (NCT03736122) | BioSyngen Pte Ltd | 2019-01-01 |
| A Randomized Study of Primary Tumor Radiotherapy for Patients With MPE Stage IV NSCLC (NCT03987087) | Guizhou Medical University | 2018-09-01 |
| Management of Malignant Pleural Effusions Using an Indwelling Tunneled Pleural Catheter and Non-Vacuum Collection System (NCT03414905) | Washington University School of Medicine | 2018-07-09 |
| Betadine Pleurodesis Via Tunneled Pleural Catheters (NCT02975921) | Yale University | 2018-07-01 |
| AMPLE-3: IPC Plus Talc vs VATS in Management of Malignant Pleural Effusion (NCT04322136) | The University of Western Australia | 2018-05-29 |
| Rocket® Pleural Catheters: QOL, Feasibility and Satisfaction in Recurrent MPE Patients (NCT03403855) | Ottawa Hospital Research Institute | 2018-03-07 |
| Activity Behaviours in Patients With Malignant Pleural Effusion (NCT03482570) | The University of Hong Kong | 2018-01-31 |
| Malignant Pleural Effusion: Pleur-X vs. Chemical Pleurodesis in VATS (NCT03518788) | Rolf Inderbitzi | 2018-01-25 |
| UNC Pleural Fluid Registry (NCT05620329) | UNC Lineberger Comprehensive Cancer Center | 2018-01-24 |
| Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer (NCT02942043) | Peking University Cancer Hospital & Institute | 2016-10-01 |
| Safety and Effectiveness of a New Pleural Catheter for Symptomatic, Recurrent, MPEs Versus Approved Pleural Catheter (NCT02649894) | C. R. Bard | 2016-05-01 |
| Clinical Trial of Tumor Cell-derived Microparticles Packaging Chemotherapeutic Drugs to Treat Malignant Pleural Effusion (NCT02657460) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2016-01-01 |
| Efficacy of Iodopovidone Versus Talc in Palliative Malignant Pleural Effusion (NCT02674243) | Chiang Mai University | 2015-11-01 |
| A Study to Compare the Efficacy and Safety of Intrapleural Doxycycline Versus Iodopovidone for Performing Pleurodesis in Malignant Pleural Effusion (NCT02583282) | Post Graduate Institute of Medical Education and Research, Chandigarh | 2015-08-01 |
| Recombinant Adenoviral Human p53 Gene in Treatment of Malignant Pleural Effusion (NCT02429726) | Shenzhen SiBiono GeneTech Co.,Ltd | 2015-06-01 |
| Using Thoracic Ultrasound to Predict Pleurodesis Success in Malignant Pleural Effusions: a Pilot Study (NCT02625675) | University of Oxford | 2015-03-19 |
| Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer (NCT02132884) | Fox Chase Cancer Center | 2015-03-01 |
| Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02122185) | University of Chicago | 2015-02-25 |
| Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer (NCT02054052) | Haihong Yang, MD, Pricipal investigator | 2014-01-01 |
| Safety and Effectiveness Study of Tumor Cell-derived Microparticles to Treat Malignant Ascites and Pleural Effusion (NCT01854866) | Huazhong University of Science and Technology | 2013-05-01 |
| Efficacy and Safety of Bevacizumab Versus Pulvis Talci in Malignant Pleural Effusion (NCT02054078) | Tang-Du Hospital | 2012-01-01 |
| Effectiveness of Doxycycline for Treating Pleural Effusions Related to Cancer in an Outpatient Population (NCT01411202) | Ottawa Hospital Research Institute | 2011-06-01 |
| Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites (NCT01327235) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2011-03-01 |
| Efficacy and Safety Study of Abnoba Viscum F 20mg in Malignant Pleural Effusion Patients (NCT02191540) | Abnoba Korea | 2011-01-01 |
| Cediranib as Palliative Treatment in Patients With Symptomatic Malignant Ascites or Pleural Effusion (NCT01262612) | Radboud University Medical Center | 2010-04-01 |
| Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer (NCT01004510) | Peter Bushunow MD | 2009-11-01 |
| Safety and Effectiveness Study for Pleurodesis With Silver Nitrate in Malignant Pleural Effusion (NCT01125124) | University of Sao Paulo General Hospital | 2009-08-01 |
| The First Therapeutic Intervention in Malignant Pleural Effusion Trial (NCT00896285) | University of California, Davis | 2009-04-01 |
| Tunneled Pleural Catheter in Partially Entrapped Lung (NCT00637676) | Heidelberg University | 2008-07-01 |
| FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer (NCT00564733) | University of Washington | 2007-10-01 |
| Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer (NCT00408460) | University of Washington | 2006-02-01 |
| Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer (NCT00126581) | National Cancer Institute (NCI) | 2005-08-15 |
| Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer (NCT00118183) | National Cancer Institute (NCI) | 2005-07-01 |
| Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer (NCT00052338) | National Cancer Institute (NCI) | 2002-09-01 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (NCT00004074) | National Cancer Institute (NCI) | 1999-08-01 |